VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

S. agalactiae Rib Protein Vaccine
Vaccine Information
  • Vaccine Name: S. agalactiae Rib Protein Vaccine
  • Target Pathogen: Streptococcus agalactiae
  • Target Disease: Group B streptococcus (GBS) infection
  • Vaccine Ontology ID: VO_0004051
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Purified Rib protein
  • rib gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Immunization Route: subcutaneous injection
Host Response

Mouse Response

  • Host Strain: C3H/HeN
  • Vaccination Protocol: Male C3H/HeN mice, 7 to 13 weeks old, were immunized subcutaneously with 25 μg of pure protein (Rib or bovine serum albumin [BSA]) in 0.1 ml of phosphate-buffered saline (PBS) mixed with 0.1 ml of complete Freund’s adjuvant. Four weeks later the mice were given boosters of the same amount of protein with incomplete Freund’s adjuvant (Larsson et al., 1996).
  • Challenge Protocol: Two weeks after the booster, the mice were injected intraperitoneally (i.p.) with a 90% lethal dose (LD90) of log-phase bacteria, diluted in 0.5 ml of Todd-Hewitt broth. The LD90 for the different strains varied between 106 and 107 bacteria, as determined in preliminary experiments (Larsson et al., 1996).
  • Efficacy: Vaccination of mice with the Rib protein protected against two strains of capsular type III and two strains of type II (Larsson et al., 1996).
References
Larsson et al., 1996: Larsson C, Stålhammar-Carlemalm M, Lindahl G. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Infection and immunity. 1996; 64(9); 3518-3523. [PubMed: 8751893].